Peer-reviewed veterinary case report
Nimustine treatment results and side effects in cats with lymphoma
By Sakai, Kosei et al.·Published in Veterinary medicine and science·2022·Graduate School of Life and Environmental Sciences, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective evaluation of nimustine use in the treatment of feline lymphoma.
- Species:
- cat
Plain-English summary
Nine cats with lymphoma (a type of cancer) were treated with a medication called nimustine to see how well it worked and what side effects it caused. Most cats experienced mild side effects like diarrhea and vomiting, but nothing severe. The cats that received nimustine as their first treatment lived a median of about 510 days, while those who received it later lived about 109 days. Overall, nimustine was well tolerated and showed promising results, suggesting it could be a good alternative to another similar drug called lomustine for treating lymphoma in cats.
People also search for: cat lymphoma treatment · nimustine for cats · side effects of lymphoma treatment in cats
Abstract
BACKGROUND: Nimustine, similar to lomustine, is an alkylating agent from the nitrosourea family. There have been some reports regarding lomustine treatment for tumour-bearing cats. However, information regarding nimustine treatment for tumour-bearing cats is limited. OBJECTIVES: To retrospectively evaluate adverse events and clinical outcomes in tumour-bearing cats receiving nimustine. METHODS: Information regarding diagnosis, treatment condition, adverse events, and clinical outcomes was collected in tumour-bearing cats receiving nimustine through reviews of medical records. RESULTS: Nine cats with lymphoma were treated with nimustine in the primary therapy (n = 2) and in the rescue therapy (n = 7). Median starting dose of nimustine was 25 mg/m(range: 20-30 mg/m) with dosing interval of three weeks and 1-11 administrations. Adverse events were mild gastrointestinal toxicity (grade 1) including diarrhoea (n = 2) and vomiting (n = 2) and mild myelosuppression (grade 1 or 2) including thrombocytopenia (n = 3) and neutropenia (n = 1). No severe adverse events were observed. Progression-free survival durations among cats receiving nimustine in the primary therapy and in the rescue therapy were 274-688 days (median: 481 days) and 9-671 days (median: 102 days), respectively. Overall survival durations among cats receiving nimustine in the primary therapy and in the rescue therapy were 275-745 days (median: 510 days) and 14-671 days (median: 109 days), respectively. CONCLUSIONS: Nimustine was well tolerated and showed clinical outcomes similar to lomustine in cats with lymphoma. These findings suggest that nimustine might be an alternative to lomustine in the treatment of feline lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34599792/